Ibane Abasolo, obtained the degrees in Biochemistry and Biology from the University of Navarra (Spain) in 1997 and 1998, respectively. During her PhD in the labs of Dr. Alfonso Calvo  (CIMA, Pamplona, Spain) and Prof. Zhou Wang (Northwestern University, Chicago, USA), she studied the role of a peptidic hormone, adrenomedullin, in prostate cancer.

Afterwards, Dr. Abasolo continued her post-doctoral training in the group of Prof. F.X. Real (IMIM, Barcelona), where she focused on the study of key factors on the progression of pancreatic cancer and cerebellar development. During this time, she gained extensive experience in experimental mouse models, including all the steps from the generation of new transgenic models, to the molecular and cellular characterization of previously existing ones.

In 2006 Dr. Abasolo moved to the Insitut d’Alta Tecnologia (PRBB, Barcelona), where she got trained in molecular imaging techniques such as the microPET, SPECT and CT.

Since 2007, Dr. Abasolo is the coordinator of the Area of Functional Validation & Preclinical Research (FVPR) of the CIBBIM-Nanomedicine. Within this area, she is in charge of developing standardized assays for testing the activity and function of candidate genes, target molecules and therapeutic compounds, and providing the industry and other research groups with an optimum technological platform for testing new biomedical applications based on nanotechnology.

Dr. Ibane Abasolo has participated in several international R&D projects (2 Euronanomed projects, 1 ERA-IB, 1 NMP11, 1 Capacitation Program in Nanotechnology) and is currently leading one Euronanomed project (DiamESTar) and is the leader at VHIR of the Smart4Fabry project (NMBP-10-2016 call) coordinated by the CIBER-BBN. She has also leaded as a PI a project within the national industry-public research cooperation program (INNPACTO-Polysfera) that included the in vitro and in vivo testing of nanomaterials for cancer treatment.

She is also directly dealing with many of the coordinated intramural projects of the Spanish Network for Nanomedicine, Centro de Investigación Biomédica en Red – Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), with the participation of the Drug Delivery and Targeting group. Moreover, as PI, she currently involved in project for targeting breast cancer stem cell using nanotechnology (Marató TV3- Pentri).